Entrar/Registro  
INICIO ENGLISH
 
Dermatología Revista Mexicana
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Dermatología Revista Mexicana >Año 2014, No. 3


Ávila A, Amaya M, Martínez JD, Moreno J
Panorama actual de las alternativas en el tratamiento de la cicatriz hipertrófica y queloide
Dermatología Rev Mex 2014; 58 (3)

Idioma: Español
Referencias bibliográficas: 89
Paginas: 247-261
Archivo PDF: 569.39 Kb.


Texto completo




RESUMEN

El tratamiento de la cicatriz hipertrófica y cicatriz queloide es un gran reto clínico para el dermatólogo, pues aunque hay diversas opciones, no existe una que sea efectiva para todos los pacientes. Debido a esto, existe un gran arsenal clínico que incluye esteroides intralesionales, antineoplásicos, inmunomoduladores, antiinflamatorios, productos tópicos de mostrador, biológicos, criocirugía y láser, entre otros. En esta revisión discutimos algunas de las opciones, su efectividad y su mecanismo de acción para la prevención y tratamiento de este padecimiento y cómo los tratamientos combinados dan mejores resultados. Asimismo, se analizan las tratamientos innovadores contra esta afección tan compleja, que suele frustrar al paciente y al médico.


Palabras clave: cicatriz hipertrófica, queloide, triamcinolona, bleomicina, criocirugía, láser.


REFERENCIAS

  1. Zurada JM, Kriegel D, Davis IC. Topical treatments for hypertrophic scars. J Am Acad Dermatol 2006;55:1024-1031.

  2. Teller P, White TK. The physiology of wound healing: injury through maturation. Surg Clin North Am 2009;89:599-610.

  3. Naylor MC, Brissett AE. Current concepts in the etiology and treatment of keloids. Facial Plast Surg 2012;28:504-512.

  4. Ferguson MW, OKane S. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention. Philos Trans R Soc Lond B Biol Sci 2004;359:839-850.

  5. Profyris C, Tziotzios C, Do Vale I. Cutaneous scarring: Pathophysiology, molecular mechanisms, and scar reduction therapeutics. Part I. The molecular basis of scar formation. J Am Acad Dermatol 2012;66:1-10.

  6. Wolfram D, Tzankov A, Pulzl P, Piza-Katzer H. Hypertrophic scars and keloids-a review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg 2009;35:171-181.

  7. Uyesugi B, Lippincott B, Dave S. Treatment of a painful keloid with botulinum toxin type A. Am J Phys Med Rehabil 2010;89:153-155.

  8. Mrowietz U, Seifert O. Keloid scarring: new treatments ahead. Actas Dermosifiliogr 2009;100:75-83.

  9. Darougheh A, Asilian A, Shariati F. Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. Clin Exp Dermatol 2009;34:219-223.

  10. Davis SA, Feldman SR, McMichael AJ. Management of keloids in the United States, 1990-2009: an analysis of the National Ambulatory Medical Care Survey. Dermatol Surg 2013;39:988-994.

  11. Syed F, Bayat A. Superior effect of combination vs single steroid therapy in keloid disease: a comparative in vitro analysis of glucocorticoids. Wound Repair Regen 2013;21:88-102.

  12. Weshahy AH, Abdel Hay R. Intralesional cryosurgery and intralesional steroid injection: a good combination therapy for treatment of keloids and hypertrophic scars. Dermatol Ther 2012;25:273-276.

  13. Hirshowitz B, Lerner D, Moscona AR. Treatment of keloid scars by combined cryosurgery and intralesional corticosteroids. Aesthetic Plast Surg 1982;6:153-158.

  14. Ud-Din S, Bowring A, Derbyshire B, Morris J, Bayat A. Identification of steroid sensitive responders versus non-responders in the treatment of keloid disease. Arch Dermatol Res 2013;305:423-432.

  15. Kill J. Keloids treated with topical injections of triamcinolone acetonide (kenalog): immediate and long-term results. Scand J Plast Reconstr Surg 1977;11:169-172.

  16. Hayashi T, Furukawa H, Oyama A, Funayama E, et al. A new uniform protocol of combined corticosteroid injections and ointment application reduces recurrence rates after surgical keloid/hypertrophic scar excision. Dermatol Surg 2012;38:893-897.

  17. Diegelmann RF, Lindblad WJ. Intralesional 5-FU in the treatment of hypertrophic scars and keloids: Clinical Experience. Dermatol Surg 1999;25:224-232.

  18. Manuskiatti W, Fitzpatrick RE. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol 2002;138:1149-1155.

  19. Nanda S, Reddy BS. Intralesional 5-fluorouracil as a treatment modality of keloids. Dermatol Surg 2004;30:54- 56,6-7.

  20. Sadeghinia A, Sadeghinia S. Comparison of the efficacy of intralesional triamcinolone acetonide and 5-fluorouracil tattooing for the treatment of keloids. Dermatol Surg 2012;38:104-109.

  21. Saha AK, Mukhopadhyay M. A comparative clinical study on role of 5-flurouracil versus triamcinolone in the treatment of keloids. Indian J Surg 2012;74:326-329.

  22. Naeini FF, Najafian J, Ahmadpour K. Bleomycin tattooing as a promising therapeutic modality in large keloids and hypertrophic scars. Dermatol Surg 2006;32:1023-1029, 9-30.

  23. Rodas-Espinoza AF, Alcalá PD, Peralta PML. Efectividad de la bleomicina intralesional para el tratamiento de pacientes con cicatrices queloides. Estudio comparativo con dexametasona. Dermatol Rev Mex 2011;55:119-126.

  24. Camacho-Martínez FM, Rey ER, Serrano FC, Wagner A. Results of a combination of bleomycin and triamcinolone acetonide in the treatment of keloids and hypertrophic scars. An Bras Dermatol 2013;88:387-394.

  25. Bailey JN, Waite AE, Clayton WJ, Rustin MH. Application of topical mitomycin C to the base of shave-removed keloid scars to prevent their recurrence. Br J Dermatol 2007;156:682-686.

  26. Seo SH, Sung HW. Treatment of keloids and hypertrophic scars using topical and intralesional mitomycin C. J Eur Acad Dermatol Venereol 2012;26:634-638.

  27. Berman B, Duncan MR. Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J Am Acad Dermatol 1989;21:694-702.

  28. Berman B, Flores F. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections. J Am Acad Dermatol 1997;37:755-757.

  29. Chuangsuwanich A, Gunjittisomram S. The efficacy of 5% imiquimod cream in the prevention of recurrence of excised keloids. J Med Assoc Thai 2007;90:1363-1367.

  30. Berman B, Kaufman J. Pilot study of the effect of postoperati ve imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol 2002;47:209-211.

  31. Prado A, Andrades P, Benítez S, Umana M. Scar management after breast surgery: preliminary results of a prospective, randomized, and double-blind clinical study with aldara cream 5% (imiquimod). Plast Reconstr Surg 2005;115:966-972.

  32. Kim A, DiCarlo J, Cohen C, McCall C, et al. Are keloids really “gli-loids”?: High-level expression of gli-1 oncogene in keloids. J Am Acad Dermatol 2001;45:707-711.

  33. Gisquet H, Liu H, Blondel WC, Leroux A, et al. Intradermal tacrolimus prevent scar hypertrophy in a rabbit ear model: a clinical, histological and spectroscopical analysis. Skin Res Technol 2011;17:160-166.

  34. Berman B, Patel JK, Pérez OA, Viera MH, et al. Evaluating the tolerability and efficacy of etanercept compared to triamcinolone acetonide for the intralesional treatment of keloids. J Drugs Dermatol 2008;7:757-761.

  35. Gallant-Behm CL, Mustoe TA. Occlusion regulates epidermal cytokine production and inhibits scar formation. Wound Repair Regen 2010;18:235-244.

  36. Gold MH, Foster TD, Adair MA, Burlison K, Lewis T. Prevention of hypertrophic scars and keloids by the prophylactic use of topical silicone gel sheets following a surgical procedure in an office setting. Dermatol Surg 2001;27:641-644.

  37. O’Brien L, Jones DJ. Silicone gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev 2013;9:3826.

  38. Chernoff WG, Cramer H, Su-Huang S. The efficacy of topical silicone gel elastomers in the treatment of hypertrophic scars, keloid scars, and post-laser exfoliation erythema. Aesthetic Plast Surg 2007;31:495-500.

  39. de Giorgi V, Sestini S, Mannone F, Papi F, et al. The use of silicone gel in the treatment of fresh surgical scars: a randomized study. Clin Exp Dermatol 2009;34:688-693.

  40. Mustoe TA, Cooter RD, Gold MH, Hobbs FD, et al. International clinical recommendations on scar management. Plast Reconstr Surg 2002;110:560-571.

  41. Phillips TJ, Gerstein AD, Lordan V. A randomized controlled trial of hydrocolloid dressing in the treatment of hypertrophic scars and keloids. Dermatol Surg 1996;22:775-778.

  42. Augusti KT. Therapeutic values of onion (Allium cepa L.) and garlic (Allium sativum L.). Indian J Exp Biol 1996;34:634- 640.

  43. Cho JW, Cho SY, Lee SR, Lee KS. Onion extract and quercetin induce matrix metalloproteinase-1 in vitro and in vivo. Int J Mol Med 2010;25:347-352.

  44. Chung VQ, Kelley L, Marra D, Jiang SB. Onion extract gel versus petrolatum emollient on new surgical scars: prospective double-blinded study. Dermatol Surg 2006;32:193-197.

  45. Koc E, Arca E, Surucu B, Kurumlu Z. An open, randomized, controlled, comparative study of the combined effect of intralesional triamcinolone acetonide and onion extract gel and intralesional triamcinolone acetonide alone in the treatment of hypertrophic scars and keloids. Dermatol Surg 2008;34:1507-1514.

  46. Saito M, Yamazaki M, Maeda T, Matsumura H, et al. Pirfenidone suppresses keloid fibroblast-embedded collagen gel contraction. Arch Dermatol Res 2012;304:217-222.

  47. Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J, Armendáriz-Borunda J. The multifaceted role of pirfe nidone and its novel targets. Fibrogenesis Tissue Repair 2010;3:16.

  48. Armendáriz-Borunda J, Lyra-González I, Medina-Preciado D, González-García I, et al. A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients. Ann Plast Surg 2012;68:22-28.

  49. Sawada Y, Sone K. Treatment of scars and keloids with a cream containing silicone oil. Br J Plast Surg 1990;43:683- 688.

  50. Sawada Y, Sone K. Hydration and occlusion treatment for hypertrophic scars and keloids. Br J Plast Surg 1992;45:599- 603.

  51. Ernst K, Hundeiker M. Results of cryosurgery in 394 patients with hypertrophic scars and keloids. Hautarzt 1995;46:462- 466.

  52. Dalkowski A, Fimmel S, Beutler C, Zouboulis ChC. Cryotherapy modifies synthetic activity and differentiation of keloidal fibroblasts in vitro. Exp Dermatol 2003;12:673-681.

  53. Goldenberg G, Luber AJ. Use of intralesional cryosurgery as an innovative therapy for keloid scars and a review of current treatments. J Clin Aesthet Dermatol 2013;6:23- 26.

  54. Yamawaki S, Naitoh M, Ishiko T, Muneuchi G, Suzuki S. Keloids can be forced into remission with surgical excision and radiation, followed by adjuvant therapy. Ann Plast Surg 2011;67:402-406.

  55. Ogawa R, Yoshitatsu S, Yoshida K, Miyashita T. Is radiation therapy for keloids acceptable? The risk of radiation-induced carcinogenesis. Plast Reconstr Surg 2009;124:1196- 1201.

  56. Ogawa R, Miyashita T, Hyakusoku H, Akaishi S, et al. Postoperative radiation protocol for keloids and hypertrophic scars: statistical analysis of 370 sites followed for over 18 months. Ann Plast Surg 2007;59:688-691.

  57. Berman B, Bieley HC. Adjunct therapies to surgical management of keloids. Dermatol Surg 1996;22:126-130.

  58. Ferguson G. Intralesional steroid injection following keloid surgery. Plast Reconstr Surg 1994;93:643.

  59. Akaishi S, Ogawa R, Hyakusoku H. Treatment of recurrent earlobe keloids with surgery and high-dose-rate brachytherapy. Plast Reconstr Surg 2009;123:424-425.

  60. Copcu E, Sivrioglu N, Oztan Y. Combination of surgery and intralesional verapamil injection in the treatment of the keloid. J Burn Care Rehabil 2004;25:1-7.

  61. Eke U, Díaz C, Abdullah A. Keloid scars in type VI skin successfully treated with combined surgery and pulsed dye laser therapy. Br J Dermatol 2013;168:1360-1362.

  62. Onwukwe MF. Treating keloids by surgery and methotrexate. Arch Dermatol1980;116:158.

  63. Llombart B, Serra-Guillén C, Monteagudo C, López Guerrero JA, Sanmartin O. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management. Semin Diagn Pathol 2013;30:13-28.

  64. Haedersdal M, Moreau KE, Beyer DM, Nymann P, Alsbjorn B. Fractional nonablative 1540 nm laser resurfacing for thermal burn scars: a randomized controlled trial. Lasers Surg Med 2009;41:189-195.

  65. Arvizu Ramírez F, Ávila Romay A, Padilla Benítez T, Núñez Luna V, Chávez Chávez M. Tratamiento láser en niños con cicatrices postquemadura. Dermatología CMQ 2013;11:237-242.

  66. Choi JE, Oh GN, Kim JY, Seo SH, et al. Ablative fractional laser treatment for hypertrophic scars: comparison between Er:YAG and CO2 fractional lasers. J Dermatolog Treat 2013.

  67. Hultman CS, Edkins RE, Wu C, Calvert CT, Cairns BA. Prospective, before-after cohort study to assess the efficacy of laser therapy on hypertrophic burn scars. Ann Plast Surg 2013;70:521-526.

  68. Waibel JS, Wulkan AJ, Shumaker PR. Treatment of hypertrophic scars using laser and laser assisted corticosteroid delivery. Lasers Surg Med 2013;45:135-140.

  69. Clayton JL, Edkins R, Cairns BA, Hultman CS. Incidence and management of adverse events after the use of laser therapies for the treatment of hypertrophic burn scars. Ann Plast Surg 2013;70:500-505.

  70. Mamalis AD, Lev-Tov H, Nguyen DH, Jagdeo JR. Laser and light-based treatment of keloids-a review. J Eur Acad Dermatol Venereol 2013.

  71. Vrijman C, van Drooge AM, Limpens J, Bos JD, et al. Laser and intense pulsed light therapy for the treatment of hypertrophic scars: a systematic review. Br J Dermatol 2011;165:934-942.

  72. Steinstraesser L, Flak E, Witte B, Ring A, et al. Pressure garment therapy alone and in combination with silicone for the prevention of hypertrophic scarring: randomized controlled trial with intraindividual comparison. Plast Reconstr Surg 2011;128:306-313.

  73. Reno F, Grazianetti P, Stella M, Magliacani G, et al. Release and activation of matrix metalloproteinase-9 during in vitro mechanical compression in hypertrophic scars. Arch Dermatol 2002;138:475-478.

  74. Anzarut A, Olson J, Singh P, Rowe BH, Tredget EE. The effectiveness of pressure garment therapy for the prevention of abnormal scarring after burn injury: a meta-analysis. J Plast Reconstr Aesthet Surg 2009;62:77-84.

  75. Carbajosa J. Queloides del lóbulo de la oreja: tratamiento con compresión externa. Dermatol Rev Mex 1992;36:366- 368.

  76. Sherris DA, Gassner HG. Botulinum toxin to minimize facial scarring. Facial Plast Surg 2002;18:35-39.

  77. Jablonka EM, Sherris DA, Gassner HG. Botulinum toxin to minimize facial scarring. Facial Plast Surg 2012;28:525-535.

  78. Zhibo X, Miaobo Z. Intralesional botulinum toxin type A injection as a new treatment measure for keloids. Plast Reconstr Surg 2009;124:275-277.

  79. Gauglitz GG, Bureik D, Dombrowski Y, Pavicic T, et al. Botulinum toxin A for the treatment of keloids. Skin Pharmacol Physiol 2012;25:313-318.

  80. Woffles TL, Wu. Skin resurfacing with Microbotox and the treatment of keloids. Botulinum Toxins in Clinical Aesthetic Practice. 2nd ed. Informa Healthcare, 2011;190-205.

  81. Ud-Din S, Bayat A. Strategic management of keloid disease in ethnic skin: a structured approach supported by the emerging literature. Br J Dermatol 2013;169:71-81.

  82. Ud-Din S, Thomas G, Morris J, Bayat A. Photodynamic therapy: an innovative approach to the treatment of keloid disease evaluated using subjective and objective non-invasive tools. Arch Dermatol Res 2013;305:205-214.

  83. Tolerton SK, Tonkin MA. Keloid formation after syndactyly release in patients with associated macrodactyly: management with methotrexate therapy. J Hand Surg Eur Vol 2011;36:490-497.

  84. Berman B, Duncan MR. Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphoea skin and their production of collagen, glycosaminoglycans and fibronectin. Br J Dermatol 1990;123:339-346.

  85. Sigler A. Use of colchicine to prevent recurrence of ear keloids. A new approach. J Plast Reconstr Aesthet Surg 2010;63:650-652.

  86. Gutiérrez Gómez C, Guinto Balanzar P, Andrade Delgado L, Alfaro Rodríguez HJ. Uso de colchicina como adyuvante en el tratamiento de cicatrices queloides recidivantes. Reporte de un caso. Cirugía Plástica 2001;11:128-130.

  87. D’Andrea F, Brongo S, Ferraro G, Baroni A. Prevention and treatment of keloids with intralesional verapamil. Dermatology 2002;204:60-62.

  88. Iannello S, Milazzo P, Bordonaro F, Belfiore F. Low-dose enalapril in the treatment of surgical cutaneous hypertrophic scar and keloid–two case reports and literature review. MedGenMed 2006;8:60.

  89. Gragnani A, Warde M, Furtado F, Ferreira LM. Topical tamoxifen therapy in hypertrophic scars or keloids in burns. Arch Dermatol Res 2010;302:1-4.



>Revistas >Dermatología Revista Mexicana >Año2014, No. 3
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019